Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

The study also included an 18-week open-label phase, during which patients with Schizophrenia were treated with Lumateperone 42 mg per day. The biopharmaceutical company found that the time to relapse ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

A woman named Li suffered from a severe psychological breakdown after she got scolded at her workplace in China. The ...

is catatonia: characterised by a host of abnormal motor behaviours occurring alongside stupor or excitement. It is no longer ...

Preliminary results demonstrated a dose-dependent effect of ANAVEX ® 3-71 on two key EEG biomarkers in patients with schizophrenia. Treatment with ANAVEX ® 3-71 compared to placebo resulted in ...

The data published in The Lancet is being heralded as a big breakthrough in the treatment of cervical cancer and uses readily available chemotherapy drugs, given to patients before they receive ...

Schizophrenia may be misdiagnosed as depression or bipolar disorder, which delays treatment and negatively impacts the prognosis, explained Megan Ehret, PharmD, MS, BCPP, of the University of ...

Because the condition is so heterogeneous, the presence of symptoms from these domains in the disease makes its diagnosis and treatment difficult. The development of some mental diseases, including ...

A 2012 study found 50% of people with schizophrenia don’t take their prescribed medication, and it’s not just because of side effects. A 2020 research review found we disengage with treatment ...